Fig. 2.

Leukemic clearance after cycle 2. Validated real‐time quantitative polymerase chain reaction (RT‐qPCR) markers for NPM1 and DEK::NUP214, respectively, were analysed in four patients, and all showed mutational clearance <0.1% (relative to the diagnostic level) after cycle 2. In the remaining five patients, one or two mutations were monitored for measurable residual disease (MRD) using deep sequencing (reporting the variant allele frequency). Mutation in RUNX1 was seen in four patients and was reduced to 0.74%–10.5% after cycle 2. In two of four patients with RUNX1, a FLT3‐TKD was also present, but was reduced below 0.05% after two cycles of treatment. After cycle 2, MRD levels below the detection limit for the method are indicated with open circles.